Effect of a Low Glycemic Index on Metabolic Syndrome

NCT ID: NCT02356952

Last Updated: 2016-07-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

163 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Metabolic Syndrome (MetS) is a cluster of multiple risk factors of metabolic origin associated with an increased risk of cardiovascular disease, type 2 diabetes mellitus and other diseases, including some cancers. There has been an increased interest of researchers in the relationship between MetS and diet and, specifically, Mediterranean diet would be beneficial for people with high risk of developing MetS or individuals with established MetS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Metabolic Syndrome (MetS) is a cluster of multiple risk factors of metabolic origin, associated with an increased risk of cardiovascular disease, type 2 diabetes mellitus and other diseases, including some cancers. The National Cholesterol Education Program's Adult Treatment Panel III (NCEP-ATP III) defines MetS the presence of at least three of five diagnostic criteria consisting in the measure of waist circumference, fasting glucose, systolic pressure and/or diastolic blood pressure, serum triglycerides and HDL cholesterol. The level of physical activity, smoking habits, low social class membership as well as low level of education and even a mild degree of chronic inflammation have been associated with an increased risk of MetS. Recently, there has been an increased interest of researchers in the relationship between MetS and diet, and more specifically Mediterranean Diet (MD). A problem of the contemporary MD is the quality of carbohydrates as the foods rich in carbohydrates consumed actually, such as white bread and some type of pasta, are produced with refined flour, at high glycemic index (GI) and load (GL). There are numerous studies showing that taking large amounts of high GI and GL foods is a risk factor for coronary heart disease and type 2 diabetes. To our knowledge there is no diet trial that compared the health effects of Mediterranean diets with different quality of carbohydrates. Objective of this study was to compare, in a randomized clinical trial, the effects of a simple MD, a Low Glycemic Index diet (LGID), and a Low Glycemic Index MD (LGIMD) on MetS, MetS components and other metabolic variables. For this reason, after a baseline examination, participants were randomly divided into three groups, each receiving a specific dietary intervention, and all the parameters measured at the first visit were examined again at months third and sixth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome X

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mediterranean Diet

Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).

Group Type EXPERIMENTAL

Mediterranean Diet

Intervention Type BEHAVIORAL

A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).

Low Glycemic Index Diet

Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).

Group Type EXPERIMENTAL

Low Glycemic Index Diet

Intervention Type BEHAVIORAL

A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).

Low Glycemic Index Mediterranean Diet

Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).

Group Type EXPERIMENTAL

Low Glycemic Index Mediterranean Diet

Intervention Type BEHAVIORAL

A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mediterranean Diet

A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).

Intervention Type BEHAVIORAL

Low Glycemic Index Diet

A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).

Intervention Type BEHAVIORAL

Low Glycemic Index Mediterranean Diet

A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* MetS, Subject enrolled in the MICOL study in 2005-2006

Exclusion Criteria

* Insulin treatment, Not enrolled in the MICOL study
Minimum Eligible Age

30 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alberto R Osella

MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alberto Rubén Osella, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

IRCCS "Saverio De Bellis"

Giovanni Misciagna, MD, PhD

Role: STUDY_DIRECTOR

IRCCS "Saverio De Bellis"

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Laboratory of Epidemiology and Biostatistics-IRCCS Saverio de Bellis

Castellana Grotte, BA, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Medidiet

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effectiveness of MD on MetS Patients
NCT06961682 NOT_YET_RECRUITING NA